in line with its broad transdiagnostic associations, are consequently thought to be particularly relevant to overall functioning. In contrast, GABAergic and excitatory genes were specifically enriched for shared genetic risk across BIP and SCZ. Collectively, these findings offer insight into varying levels of cross-cutting risk, from entirely transdiagnostic to a specific pair of disorders. As GWAS results may implicate effective drug targets (King, Davis, & Degner, 2019), cross-disorder mechanistic findings offer opportunities for drug repurposing or novel pharmacological targets for particularly comorbid presentations.
